Recent developments in drug resistance mechanism in chronic myeloid leukemia: A review

European Journal of Haematology

Volumn 87, Issue 5, 2011, Pages 381-393

  Vaidya, Shantashri ^a   Ghosh, Kanjaksha ^a   Vundinti, Babu Rao ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

BCR ABL fusion; Chronic myeloid leukemia; Chronic myeloid leukemia therapy; Drug resistance; Imatinib

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ABELSON KINASE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BOSUTINIB; BREAST CANCER RESISTANCE PROTEIN; CANCER VACCINE; CLINDAMYCIN; DASATINIB; DIHYDROFOLATE REDUCTASE; DNA VACCINE; ERYTHROMYCIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; MESSENGER RNA; NILOTINIB; ONO 12380; PEGINTERFERON ALPHA2A; PONATINIB; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RIBOZYME; TOZASERTIB; UNCLASSIFIED DRUG; WORTMANNIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANKLE EDEMA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BINDING AFFINITY; BINDING COMPETITION; BIOACCUMULATION; BLEEDING; BREATHING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHILL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DARK URINE; DEPRESSION; DIARRHEA; DRUG BINDING; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVE SITE; EYE JAUNDICE; FACE EDEMA; FATIGUE; FOOT EDEMA; FRAMESHIFT MUTATION; GASTROINTESTINAL SYMPTOM; HAND EDEMA; HEART PALPITATION; HEMATOCHEZIA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTOSIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUSCLE CRAMP; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE; OPEN READING FRAME; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; PRURITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BRUISING; SKIN MANIFESTATION; SOLID TUMOR; SORE THROAT; SPLENOMEGALY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WEAKNESS; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GENES, ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 80054029556     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01689.x     Document Type: Review

References (58)

1. Clarkson B. Chronic myelogenous leukemia: etiology, incidence, and clinical features. Encycl Cancer 2002;1:505-18.
2. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-55.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science 1990;247:1079-82.
5. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiolody of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-23.
6. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002;8(4 Suppl.):S14-8.
7. Azam M, Daley GQ. Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006;10:67-76.
8. Weisberg E, Griffin J. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003;6:231-8.
9. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med 2002;346:645-52.
10. Quintás-Cardama A, Kantarjian H, Cortes J. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16:122-31.
11. Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007;35:1347-51.
12. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Dasatinib targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
13. Gambacorti-Passerini CB, Gundy RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85.
14. Larghero J, Mahon FX, Madeleine-Chambrin I, et al. Elevated levels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevac (STI571, imatinib) in vitro and are associated with primary resistance in vivo. Presented at the 43rd annual meeting of the American Society of Hematology 2001, Orlando.
15. Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid myeloid leukaemia during imatinib treatment. Cancer Genet Cytogenet 2005;162:57-62.
16. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman J, Melo J. MDR1 gene overexpression confers resistance to imatinib mesylate in leukaemia cell line models. Blood 2003;101:2368-73.
17. Ferrao P, Frost MJ, Siah SP, Ashman L. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003;102:4499-503.
18. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers G, Molimard M, Krajinovic M, Mahon FX. Multidrug resistance (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-7.
19. Yamada O, Ozaki K, Furukawa T. Activation of STAT 5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal 2011;23:1119-27.
20. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR/ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic myeloid leukaemia. Cancer Cell 2002;2:117-25.
21. Nardi V, Azam M, Daley G. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35-43.
22. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI-571; a prospective study. Lancet 2002;359:487-91.
23. Hughes T. Mechanisms of resistance, common BCR-ABL mutations, and monitoring response to treatment in CML. Medscape 2008. Accessed August 17, 2011.
24. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR/ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
25. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
26. Hayette S, Chabane K, Tchirkov A, Berger M, Nicolini F, Tournilhac O. Detection of twelve nucleotide insertions in the BCR/ABL kinase domain in an imatinib resistant but dasatinib sensitive patient with bi-phenotypic acute leukemia. Haematologica 2009;94:1324-6.
27. Azam M, Latek R, Daley G. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
28. Sherbenou D, Hantschel O, Kaupe I. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 2010;116:3278-85.
29. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
30. Barnes D, Schultheis B, Adedeji S, Melo J. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005;24:6432-40.
31. Hochhaus A, Kreil S, Corbin AS. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
32. Weisberg E, Griffin J. Mechanism of resistance to theABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
33. Weisberg E, Manley PW, Breitenstein W. Characterization of AMN107, a selective inhibitor of native and mutant BCR/ABL. Cancer Cell 2005;7:129-41.
34. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
35. O'Hare T, Shakespeare W, Zhu X, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcome mutation-based resistance. Cancer Cell 2009;16:401-12.
36. Zhou T, Commodore L, Huang WS, et al Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011;77:1.
37. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-81.
38. Cortes-Franco J, Kantarjian H, Kim DW, Khoury HJ, Turkina A, Shen ZX, Brummendorf TH, Chandy M, Arkin S, Gambacorti-Passerini C. Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML). Blood 2007;110:11.
39. Bartholomeusz G, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato N. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007;109:3470-8.
40. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-2.
41. Zhang B, Guilhot J, Nicolini FE. Effective targeting of quiescent chronic myelogenous leukemic stem cells by histone deacetylase inhibitors in combination with imatinib mesylate cancer. Cell 2010;17:427-42.
42. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21.
43. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429-35.
44. Kim J Chu S, Gramlich J, Pride Y, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin J, Sattler M, et al. Activation of the PI3K/mTOR pathway by BCR/ABL contributes to increased production of reactive oxygen species. Blood 2005;105:1717-23.
45. Lucansky V, Sobotkova E, Tachezy R, Duskova M, Vonka V. DNA vaccination against bcr-abl positive cells in mice. Int J Oncol 2009;35:941-51.
46. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpointfusion peptides generates specific immune responses. Blood 2000;95:1781-7.
47. Wohlbold L, van der Kuip H, Miething C, Vornlocher H, Knabbe C, Duyster J, Aulitzky W. Inhibition of BCR/ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI-571). Blood 2003;2:2236-9.
48. Melo J, Hughes T, Apperley J. Chronic myeloid leukemia. Am Soc Hematol 2003;1:132-52.
49. Clark RE. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 2000;14:347-55.
50. Dhut S, Chaplin T, Young BD. BCR/ABL and BCR proteins: biochemical characterization and localization. Leukemia 1990;4:745-50.
51. Leopold L, Shore S, Newkirk TA, Reddy R, Reddy EP. Multi-Unit Ribozyme-Mediated Cleavage of bcr-abl mRNA in Myeloid Leukemias. Blood 1995;85:2162-70.
52. Beissert T, Puccetti E, Bianchini A, Güller S, Boehrer S, Hoelzer D, Ottmann OG, Nervi C, Ruthardt M. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003;102:2985-93.
53. Vigneri P, Wang J. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001;7:228-34.
54. Parikh P, Saikia T, Tripathi A, Shah S, Sheth A, Shah P. Role of Imatinib Mesylate in Chronic Myeloid Leukemia. In: Agarwal MB, ed. Chronic Myeloid Leukemia, 1st edn. Mumbai: Ranbaxy Super Specialities Ranbaxy House, 2007:89-105.
55. Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol 2011. doi: Epub ahead of print.
56. Garg R, Kantarjian H, O'Brien S, Quinta′s-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow up. Blood 2009;114:4361-8.
57. DiBella N. First-line treatment of chronic myeloid leukemia: imatinib versus nilotinib and dasatinib. Commun Oncol 2011;8:65-72.
58. Nelson R. Bosutinib effective as second- and third-line therapy in CML. ASCO 2010 Annual Meeting.